Although no MPR was found in EGFR/ALK-positive NSCLC treated with neoadjuvant atezolizumab alone regarding the LCMC3 study,34 a phase II study enrolled 4 patients with EGFR mutations, of whom 2 achieved pCR after neoadjuvant atezolizumab plus chemotherapy.20 The gene discussed is ALK; the disease is non-small cell lung carcinoma.